Cytokinetics (CYTK) Tops Q2 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $61.23 -1.76%
EPS Growth %: +43.1%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +43.1%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($1.50), $0.13 better than the analyst estimate of ($1.63). Revenue for the quarter came in at $28.6 million versus the consensus estimate of $17.09 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kotak Upgrades Indusind Bank Ltd (IIB:IN) to Reduce (3)
- Kotak Upgrades Torrent Pharma (TRP:IN) to Buy (1)
- Jefferies Upgrades Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (RDY) to Hold
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
